← Back to Search

Other

Gravity vs. Vacuum Drainage Systems for Pleural Effusion (NEWTON Trial)

Seattle, WA
N/A
Recruiting
Led By Lonny Yarmus, DO
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histocytological proof of pleural malignancy
Plans for placement of IPC within ten days of enrollment
Must not have
Respiratory failure
Inability to follow-up for appointments/protocol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-ipc placement, 12 weeks post ipc placement or time of pleurodesis
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether gravity drainage or suction drainage is better for people with a debilitating complication of end stage cancer.

See full description
Who is the study for?
This trial is for adults over 17 with malignant pleural effusion, who've felt better after draining fluid from the chest. They must be able to safely have a catheter inserted and manage its care. Excluded are those with certain conditions like bleeding disorders, recent chest surgeries or trauma, very short life expectancy, or current infections.Check my eligibility
What is being tested?
The study compares two ways of draining fluid buildup in the chest due to cancer: using gravity or vacuum suction through an indwelling tunneled pleural catheter (IPC). It aims to see which method improves quality of life and has better outcomes.See study design
What are the potential side effects?
Potential side effects may include discomfort and chest pain during drainage. The extent of these side effects could vary based on whether gravity or vacuum suction is used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer diagnosis was confirmed with a tissue sample.
 show original
Select...
I am scheduled to get an IPC placed within 10 days of joining.
 show original
Select...
I have fluid buildup in my chest that is cancer-related.
 show original
Select...
I am older than 17 years.
 show original
Select...
I have recurring fluid buildup in my chest due to cancer that has spread.
 show original
Select...
I felt better breathing after fluid was drained from my chest.
 show original
Select...
I need a chest drain for fluid buildup due to cancer.
 show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am experiencing respiratory failure.
 show original
Select...
I can attend all required appointments.
 show original
Select...
I have painful bone metastases in my ribs or chest area.
 show original
Select...
I have had a chemical treatment to close the space in my chest previously.
 show original
Select...
I am worried I might have an infection in the lining of my lungs.
 show original
Select...
My chest fluid can't be drained well due to trapped pockets.
 show original
Select...
I have a condition that prevents my blood from clotting properly.
 show original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-ipc placement, 12 weeks post ipc placement or time of pleurodesis
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-ipc placement, 12 weeks post ipc placement or time of pleurodesis for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in chest pain as assessed by Visual Analog Scale (VAS)
Secondary study objectives
Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Dyspnea survey score
Change in SF 36-Item Health Survey score
Change in mean difference in chest pain as assessed by VAS

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GravityExperimental Treatment1 Intervention
The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
Group II: VacuumActive Control1 Intervention
The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.

Find a Location

Closest Location:Northwest Community Healthcare· Arlington Heights, IL· 298 miles

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,361 Previous Clinical Trials
15,160,280 Total Patients Enrolled
2 Trials studying Pleural Effusion
255 Patients Enrolled for Pleural Effusion
Rocket Medical plcOTHER
4 Previous Clinical Trials
458 Total Patients Enrolled
4 Trials studying Pleural Effusion
458 Patients Enrolled for Pleural Effusion
Swedish Medical CenterOTHER
54 Previous Clinical Trials
8,294 Total Patients Enrolled
Medical University of South CarolinaOTHER
990 Previous Clinical Trials
7,407,851 Total Patients Enrolled
University of OxfordOTHER
1,108 Previous Clinical Trials
16,721,140 Total Patients Enrolled
5 Trials studying Pleural Effusion
2,413 Patients Enrolled for Pleural Effusion
Vanderbilt University Medical CenterOTHER
919 Previous Clinical Trials
938,546 Total Patients Enrolled
2 Trials studying Pleural Effusion
298 Patients Enrolled for Pleural Effusion
Northwest Community HealthcareUNKNOWN
1 Previous Clinical Trials
450 Total Patients Enrolled
Lonny Yarmus, DOPrincipal InvestigatorJohns Hopkins University
5 Previous Clinical Trials
663 Total Patients Enrolled
1 Trials studying Pleural Effusion
95 Patients Enrolled for Pleural Effusion

Media Library

Gravity-Based IPC (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03831386 — N/A
Pleural Effusion Research Study Groups: Vacuum, Gravity
Pleural Effusion Clinical Trial 2023: Gravity-Based IPC Highlights & Side Effects. Trial Name: NCT03831386 — N/A
Gravity-Based IPC (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03831386 — N/A
~44 spots leftby Dec 2026